Efficacy of rotigotine as measured by individual Unified Parkinson’s Disease Rating Scale II and III items: a post-hoc analysis
Objective: The key aim was to assess the efficacy of rotigotine (RTG) transdermal patch on individual items of Unified Parkinson’s Disease Rating Scale (UPDRS) II…Validation of a performance-based assessment of functional ability related to cognition in Parkinson’s disease
Objective: Validate the University of California San Diego Performance-Based Skills Assessment (UPSA) in Parkinson's disease (PD) Background: Diagnostic criteria for PD dementia (PDD) require significant…Sample size estimation for clinical trials in de novo Parkinson’s disease (PD): Results from the Parkinson’s Progression Markers Initiative (PPMI) Study
Objective: To use clinical and biological data from PPMI to estimate sample size for disease modification studies in de novo PD Background: One barrier to…Classification of neurocognitive impairment in Spanish speaking Parkinson’s disease patients
Objective: To examine differences between United States (US) and Latin American (LA) norms classifying cognitive impairment using standardized neuropsychological measures to assess cognition in Parkinson’s…Five year longitudinal change in the MDS-UPDRS scores in early Parkinson’s disease participants: Results from the PPMI Study
Objective: To determine the longitudinal change in the Movement Disorder Society –Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) in Parkinson’s disease (PD) participants who were untreated…Which self-report motor experiences of daily living best predict objective motor function in patients with Parkinson’s disease?
Objective: To identify the most important self-reported motor experience predictors of objective measures of motor impairment in patients with Parkinson's disease (PD). Background: The MDS-UPDRS has…Improving Clinical Trials Through Patient Input: Outcomes of a Partnership Between Pfizer and the Parkinson’s Disease Foundation
Objective: To identify the outcomes of the partnership between Pfizer and the Parkinson’s Disease Foundation (PDF), which was designed to 1. increase understanding of the…Objective measurement of upper extremity bradykinesia using the keyboard-based dexterity test
Objective: To objectively assess the bradykinesia of upper extremity using the Objective Movement Disorder Measurement (OMDM)-Dexterity test Background: Bradykinesia is one of the clinical hallmarks…Association of Parkinson’s disease severity and cortical and subcortical cognitive markers
Objective: To assess cortical and subcortical dysfunction in several stages of Parkinson's disease (PD) using the Parkinson's disease-cognitive rating scale (PD-CRS). Background: Cognitive impairment in…Pantotenate kinase associated neurodegeneration (PKAN): Proposal for a clinical rating scale
Objective: To design and validate a quantitative method for the assessment of PKAN patients. Background: Despite advances in the research of novel therapies for PKAN,…
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 35
- Next Page »